FibroBiologics Inc
FBLG
Company Profile
Business description
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
Contact
455 E. Medical Center Boulevard
Suite 300
HoustonTX77598
USAT: +1 281 671-5150
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Meta earnings: Strong end to 2025 as AI monetization begins to show
Investors please with latest results.
stocks
Why doesn’t the market like the earnings from this US tech giant?
Good quarter with AI demand ramping.
stocks
Our Tesla fair value increases meaningfully
Progress on Robotaxi and Optimus shows real world AI growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,236.90 | 6.40 | -0.07% |
| CAC 40 | 8,071.36 | 4.68 | 0.06% |
| DAX 40 | 24,309.46 | 513.33 | -2.07% |
| Dow JONES (US) | 48,888.79 | 126.81 | -0.26% |
| FTSE 100 | 10,171.76 | 17.33 | 0.17% |
| HKSE | 27,968.09 | 141.18 | 0.51% |
| NASDAQ | 23,516.53 | 340.92 | -1.43% |
| Nikkei 225 | 53,375.60 | 16.89 | 0.03% |
| NZX 50 Index | 13,348.61 | 64.26 | -0.48% |
| S&P 500 | 6,926.53 | 51.50 | -0.74% |
| S&P/ASX 200 | 8,927.50 | 4.30 | 0.05% |
| SSE Composite Index | 4,157.98 | 6.75 | 0.16% |